The News
Owkin has rebranded its subsidiary Owkin Dx to Waiv, securing $33 million in financing led by OTB Ventures and Alpha Intelligence Capital. Waiv aims to enhance patient identification and stratification using AI in clinical settings.
Why It Matters
The establishment of Waiv signifies a strategic pivot towards AI-driven healthcare solutions, which could improve patient outcomes and streamline clinical trials. This move may accelerate the integration of AI in medical diagnostics, influencing future AGI applications in healthcare.
Key Evidence
The information is sourced from a reliable news outlet, finanznachrichten, detailing the funding and strategic direction of Waiv.
Original Article
finanznachrichten
DE source 路 Published 3d ago
https://www.finanznachrichten.de/nachrichten-2026-03/67928029-owkin-creates-new-spin-out-waiv-formerly-owkin-dx-with-dollar-33m-financing-004.htm